Michigan’s Bio-Industry Strategic Roadmap to be Updated

May 29, 2024

Charting the Future of Michigan’s Biosciences Industry

MichBio, the association for Michigan’s biosciences industry, announced during the 2024 Mackinac Policy Conference that it is launching a statewide effort to update the Michigan Bio-Industry Roadmap for Success. The Roadmap is a strategic plan released in early 2016 for growing Michigan’s biosciences industry into a global leader. 



“Michigan’s bio-industry is at a critical point given the rapidly changing dynamics in the worldwide marketplace and healthcare delivery landscape”, remarked Stephen Rapundalo, MichBio President and CEO. “While our statewide bio-industry cluster has witnessed good growth in recent years, other U.S. regions, many with lesser industry footprints and research innovation strength than Michigan, have been far more aggressive and successful in developing their life sciences hubs. It is imperative to develop a shared and executable vision for supporting Michigan’s bio-industry that can retain both our STEM and trades talent in high-wage jobs.” 

The updated Roadmap is an operational “game plan” to enable growth over the next five years. The planning effort will identify key strategies to expand the different sectors that make up the bio-industry including pharmaceuticals, medical products and technologies, research and testing, agricultural/industrial biotechnology, health technologies, and bioscience distribution. In addition, the initiative will define priorities for spurring innovation, improving the business climate and capital access, and developing talent for all skill levels. 


“It is important to note that the biosciences are the one industry where Michigan has all the needed ingredients to realize economic success. This begins with our world-class research institutions that deliver discoveries and serve as the substrate for commercialization, and ultimately, the development of life-changing treatments for patients,” said Britany Affolter-Caine, University Research Corridor (URC) Executive Director. “A roadmap that integrates stakeholders from across the state is critical to sustain, much less grow, an R&D and biomanufacturing ecosystem that is the envy of others.” 


The road mapping effort will be overseen by an executive steering committee comprised of bio-industry experts from around Michigan: 


Outreach to bio-industry stakeholders is planned in the form of a statewide listening tour, interviews, focus groups, and surveys. Data gathered will validate key strategic themes and areas, identify new unmet needs and growth opportunities, and help develop policy proposals for legislative action. Existing MichBio workgroups (Committees) will support the steering group in developing the Roadmap. The final report will include recommendations around goals, performance measures and responsible parties for delivering outcomes. 

“Accelerating the success of Michigan’s life science industry requires a mission-driven mindset to nurture growth,” says Rapundalo. “Our core challenge – and great opportunity – is to bring synergies together around our assets and capabilities, direct them in a manner that empowers all stakeholders, and allows the industry to flourish. The Roadmap seeks to be the beacon for executing on that mission. The time for action is now.” 


———————— 


MichBio is the only statewide trade association committed to driving growth in Michigan’s biosciences industry and its many sectors, including agricultural/industrial biotech, medical devices, pharmaceuticals, academic/clinical research, testing and research services, healthcare and information technologies, and bioscience products distribution. MichBio members include bioscience companies, research institutions, manufacturing suppliers and service providers, and related organizations. MichBio is here to support Michigan’s bioscience researchers, innovators, and producers, as well as those in the broader ecosystem that serve to sustain them. Through advocacy, programming, connecting, and business resources we help the state’s biosciences community thrive. For more information, visit www.michbio.org or follow us on LinkedIn and X. 

RECENT ARTICLES

MichBio Hiring: Intern, Association Membership & Resource Analytics

April 15, 2025
MichBio seeks a highly motivated individual who can work creatively in a small team environment and assist in data mining, compilation, and research.

Bio Survey Underscores Impacts of Tariffs for Businesses

April 11, 2025
The Biotechnology Innovation Organization (BIO), of which MichBio is a state affiliate recently released the results of a survey of its members, noting that “U.S. Biotechs Sound the Alarm” on tariff impacts. The findings include: Tariffs on European Union and Canadian imports would increase manufacturing costs for 94% and 82% of biotech firms, respectively. 70% of companies anticipate higher manufacturing costs due to tariffs on China. Tariffs on the European Union would force 50% of biotech firms to identify new research and manufacturing partners. More than 50% of biotech firms predict “increased difficulty” in funding and conducting research if EU tariffs are enacted. 80% of biotech firms would need at least 12 months to find alternative suppliers; 44% would need over two years. The survey noted that sudden tariffs would fundamentally punish American companies, threaten vital research projects and imperil United States leadership in biomedical science. Read BIO’s press release , along with an one-pager summarizing the survey results. 

Amid Proposed Cuts, Commission Calls For $15B NIH Support

April 10, 2025
A federal commission, in a new report , is calling for $15 billion in new financing to reinforce the United States’ biotech leadership amid encroaching competition from China. This comes against a backdrop where the Trump Administration has proposed severe cuts to NIH operations and funding. The National Security Commission on Emerging Biotechnology was created by Congress in 2022 to explore how biotechnology advancements could shape the economy and national security. The body quickly focused on China, as that government has gone about gathering Americans’ genetic information and intellectual property in the biotech space and resourcing their cluster’s rapid growth. The report’s 49 recommendations, organized across six strategic pillars, offer a bold and actionable framework to protect U.S. biotech intellectual property and bolster drug development, agriculture, and biological weapons defense: Prioritize biotechnology at the national level Mobilize the private sector to get U.S. products to scale Maximize the benefits of biotechnology for defense Out-innovate our strategic competitors Build the biotechnology workforce of the future Mobilize the collective strengths of our allies and partners The report calls for $1 billion to create an investment fund, more than $6 billion for large-scale research challenges, and a build-up of biomanufacturing sites across the country. Also, it calls for new legislation barring companies that work with U.S. national security agencies or health agencies from using certain Chinese biotech suppliers. The commission doesn’t have the power to authorize any changes but can make recommendations and advise members of Congress. BIO issued a statement in support.